-

Bruker Releases 2023 Sustainability Report

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today released its 2023 Sustainability Report, highlighting how Bruker’s spirit of ‘Innovation with Integrity’ is advancing science and technology, medicine and health, as well as safety and prosperity in a responsible, sustainable manner. The report also provides an overview of Bruker’s ESG strategy, initiatives and performance.

“We are pleased to introduce this inaugural 2023 Sustainability Report, which showcases our commitment to corporate social responsibility, transparency and progress in many high-impact ESG areas,” said Gerald Herman, Bruker’s Executive Vice President & CFO. “As a global innovation leader in cutting-edge scientific instruments, analytical technologies and life-science solutions, our scientists and engineers support scientific and medical researchers and advanced businesses around the world to better understand molecular, cell and disease biology, to measure and image complex systems, and search for new ways to improve our quality of life. We are especially proud to collaborate closely with many of our customers on ways to ensure a healthier, safer, and more sustainable future.”

Frank H. Laukien, Ph.D., Bruker’s President & CEO, added: “Our 2023 Sustainability Report highlights how Bruker solutions are helping scientists and technicians to address environmental challenges, advance disease research and scientific discovery, identify hazardous materials in our environment, secure the safety and authenticity of our food and materials, advance research and development of next-generation renewable energy technologies, and to improve recycling. It also reviews our initiatives to reduce environmental impact, promote social responsibility, diversity and inclusion, and to exercise the highest standards of corporate governance, all part of our long-term commitment to ‘Innovation with Integrity’.”

To access the Sustainability Report, and for more information regarding Bruker sustainability initiatives, please visit the Corporate Social Responsibility (CSR) section of our website at www.bruker.com/en/about/csr

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life-science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial research, semiconductor metrology and cleantech applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Joe Kostka
Associate Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Joe Kostka
Associate Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026

SAN DIEGO--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting. At AACR, Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research. At AACR 2026, Bruker Spatial Biology will launch new cross‑platform workflows linking GeoMx...

Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management

MUNICH--(BUSINESS WIRE)--At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker’s continued commitment to advancing integrated, high‑performance solutions that support laboratories in addressing evolving infectious disease challenges. MALDI Biotyper® Workflow and Identification Enhancements To further streamline routine MALDI‑TOF w...

Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026

MUNICH--(BUSINESS WIRE)--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operati...
Back to Newsroom